Clinical Trials Directory

Trials / Conditions / Platinum-Sensitive Ovarian Carcinoma

Platinum-Sensitive Ovarian Carcinoma

7 registered clinical trials studyying Platinum-Sensitive Ovarian Carcinoma — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingPembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patien
NCT05231122
Roswell Park Cancer InstitutePhase 2
RecruitingMeasuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT04550494
National Cancer Institute (NCI)Phase 2
Active Not RecruitingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With
NCT04092270
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr
NCT04034927
National Cancer Institute (NCI)Phase 2
TerminatedGenetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen i
NCT03691376
Roswell Park Cancer InstitutePhase 1
Active Not RecruitingCarboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ova
NCT02627443
National Cancer Institute (NCI)Phase 1
CompletedNab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance
NCT02020707
Mayo ClinicPhase 1